Published in J Immunol on January 09, 2015
Harnessing the Microbiome to Enhance Cancer Immunotherapy. J Immunol Res (2015) 0.79
Exploiting IL-17-producing CD4(+) and CD8(+) T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother (2016) 0.79
Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight (2016) 0.78
The role of IL-17 in vitiligo: A review. Autoimmun Rev (2016) 0.76
β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. JCI Insight (2017) 0.75
IL-17A-producing T cells are associated with the progression of lung adenocarcinoma. Oncol Rep (2016) 0.75
Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight (2017) 0.75
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (2000) 17.61
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 12.72
The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol (2008) 9.64
Late developmental plasticity in the T helper 17 lineage. Immunity (2009) 8.81
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature (2008) 7.00
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol (2008) 6.09
The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol (2008) 5.92
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol (2007) 5.27
Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science (2008) 4.04
Transcriptional regulation of Th17 cell differentiation. Semin Immunol (2007) 3.86
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity (2010) 3.24
Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol (2009) 3.23
CARs on track in the clinic. Mol Ther (2011) 2.86
Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity (2008) 2.78
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med (2010) 2.40
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol (2010) 2.24
Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med (2012) 2.11
Type 17 CD8+ T cells display enhanced antitumor immunity. Blood (2009) 2.02
Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 1.99
Essentials of Th17 cell commitment and plasticity. Blood (2013) 1.95
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity (2012) 1.82
A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur J Immunol (2009) 1.79
Cutting edge: Phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol (2009) 1.73
Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73
Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol (2010) 1.68
CD5 costimulation induces stable Th17 development by promoting IL-23R expression and sustained STAT3 activation. Blood (2011) 1.62
Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev (2010) 1.61
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res (2011) 1.56
IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol (2009) 1.54
IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. J Clin Invest (2012) 1.40
Th17 cells in cancer: the ultimate identity crisis. Front Immunol (2014) 1.33
IFN-γ and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur J Immunol (2010) 1.31
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J Immunol (2009) 1.23
Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol (2004) 1.22
ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur J Immunol (2002) 1.19
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med (2014) 1.18
Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res (2010) 1.14
Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol (2013) 1.11
T-cell engineering for cancer immunotherapy. Cancer J (2009) 1.09
Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci U S A (2014) 1.00
Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. J Immunol (2006) 1.00
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. J Clin Invest (2009) 1.00
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood (2009) 0.99
Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J Immunol (2013) 0.96
ICOS promotes IL-17 synthesis in colonic intraepithelial lymphocytes in IL-10-/- mice. J Leukoc Biol (2009) 0.95
Genetic modification of T-cell clones for therapy of human viral and malignant diseases. Cancer J Sci Am (1998) 0.86
Tc17 CD8+ T cells potentiate Th1-mediated autoimmune diabetes in a mouse model. J Immunol (2012) 0.84
The role of Th17/Tc17 peripheral blood T cells in psoriasis and their positive therapeutic response. Scand J Immunol (2013) 0.84
Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro. J Immunother (2011) 0.83
Protective effector memory CD4 T cells depend on ICOS for survival. PLoS One (2011) 0.82
Adoptive immunotherapy of cancer: Gene transfer of T cell specificity. Self Nonself (2011) 0.78